Anthem Biosciences’ ₹3,395-crore IPO was fully subscribed on Day 2, receiving strong investor demand with bids exceeding the shares on offer, NSE data shows.

Commercial development continued to anchor deal value in India in the April-June period this year, accounting for 62 per cent ...

WeWork India has received approval from SEBI for its IPO, with Embassy Buildcon LLP planning to sell a significant stake.

WeWork India had filed draft papers for the IPO in early February. The offer consists of 33 million equity shares held by ...

By Kashish Tandon (Reuters) -Indian drugmaker Anthem Biosciences' [ANTH.NS] $395 million IPO was fully subscribed on the second day of bidding on Tuesday, as investors bet on its growth prospects as ...

Coworking space giant WeWork India Management has secured approval from the capital markets regulator SEBI to launch its ...

WeWork India Management, an Indian flexible workspace sector, has received approval from the Securities and Exchange Board of ...

WeWork India, the leading flexible workspace provider, has secured SEBI's approval for its IPO, consisting entirely of an ...

Indian drugmaker Anthem Biosciences’ $395 million public listing was fully subscribed on the second day of bidding, as ...

Embassy-backed Wework receives SEBI nod for IPO debut with strong global brand partnerships and exclusive WeWork license in ...

WeWork India had filed draft papers for the IPO in early February. The offer consists of 33 million equity shares held by Indian real estate firm Embassy Group and 10.3 million equity shares held by 1 ...

Anthem Biosciences IPO opened for subscription on July 15, 2025, with a price band of Rs 540–570. The Rs 3,395 crore issue is entirely offer-for-sale (OFS) and will close on July 16.